Sydney East Pancreatic Centre
Home | About | Our Team | Dr. Stephen Thompson

Dr. Stephen Thompson

Dr. Stephen Thompson

Dr. Stephen Thompson

Dr Stephen Thompson (MBBS, FRANZCR, PhD) is a senior staff specialist in radiation oncology at the Nelune Comprehensive Cancer Centre at Prince of Wales Hospital, as well as conjoint senior lecturer in the faculty of medicine at UNSW. He trained at Westmead Hospital and subsequently undertook Fellowship and his PhD at Liverpool Hospital. Gastro-intestinal cancers, including pancreatic cancer, are one of his areas of sub-specialty expertise, with a particular focus on the use of IMRT (Intensity Modulated Radiotherapy), VMAT (Volumetric Modulated Arc Therapy) and IGRT (Image Guided Radiotherapy) for abdominal and pelvic malignancies, aiming to deliver safe and accurate radiotherapy. He is the Chair of the Prince of Wales Hospital Upper GIT Multi-Disciplinary Teams, including Hepato-Pancreatico-Biliary MDT, Gastro-oesophageal MDT, Neuro-endocrine MDT, and Lower GIT MDT.

Dr Thompson is heavily involved in cancer clinical research as well as training of the next generation of radiation oncologists. He is on numerous state and national Scientific Advisory Committees, including previously the radiation oncology sub-committee of the AGITG (Australasian Gastro-Intestinal Trials Group), and currently the Cancer Institute NSW Colon and Rectal Cancer Clinical Advisory Group and the Cancer Institute NSW eviQ Radiation Oncology Reference Committee – Upper Gastrointestinal and Colorectal.

Positions Held and Membership of Professional Committees

    • 2004-2005     Sydney South West Area Health Service (Western Zone) Radiation Oncology Breast Fractionation Committee
    • 2006-2007    Prince of Wales Hospital Department of Radiation Oncology Supervisor of Training
    • 2006-2007    NSW Cancer Institute Standard Cancer Treatments – Radiotherapy Committee
    • 2006-2007    RANZCR: NSW Branch Education Co-Ordinating Committee
    • 2006- present  BSOC: Basic Sciences of Oncology Steering Committee and Anatomy Coordinator
    • 2012- 2013    New South Wales Cancer Institute Oncology Groups: Upper Gastro-Intestinal
    • 2012- 2016    Prince of Wales Hospital Comprehensive Cancer Centre Grand Rounds – Inaugural Convenor thence Steering Committee
    • 2012- present  Research Associate, Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital
    • 2015- present  Quality Assurance Committee, Department of Radiation Oncology, POWH
    • 2015- present  ASSG SAC: Australasian Sarcoma Study Group Scientific Advisory Committee
    • 2016- present  Research Committee, Department of Radiation Oncology, POWH
    • 2016- present  GOROC: Gynaecology Oncology Radiation Oncology Collaborative, Royal Australian and New Zealand College of Radiologists.
    • 2017- present  TCRN (Translational Cancer Research Network, UNSW) - Scientific Advisory Board
    • 2017- present  SPHERE (Sydney Partnership for Health, Education, Research and Enterprise), CAG (Clinical Academic Group), Cancer Stream  – Management Committee
    • 2017- present  SPHERE (Sydney Partnership for Health, Education, Research and Enterprise), CAG (Clinical Academic Group), Cancer Stream, Cancers with Poor Outcomes Theme – Committee Member
    • 2017- present  AGITG (Australasian Gastro-Intestinal Trials Group) - Radiation Oncology Sub-Committee
    • 2018 – present South Eastern Sydney Local Health District Cancer Clinical Trial Steering Committee
    • 2018 – present GOROC: Gynaecology Oncology Radiation Oncology Collaborative, Royal Australian and New Zealand College of Radiologists – Gynaecological Brachytherapy Credentialing Group
    • 2018 – present Cancer Institute NSW Colon and Rectal Cancer Clinical Advisory Group
    • 2018 – present eviQ Radiation Oncology Reference Committee – Upper Gastrointestinal and Colorectal

Membership of Professional Organizations

    • 2004- present  FRANZCR: Fellow, Royal Australian and New Zealand College of Radiologists
    • 2004- present  TROG: Trans Tasman Radiation Oncology Group
    • 2004- present  ABG: Australasian Brachytherapy Group
    • 2004- present  New South Wales Neuro-Oncology Group
    • 2006- present  AGITG: Australasian Gastro-Intestinal Trials Group
    • 2009- present  ASSG: Australasian Sarcoma Study Group
    • 2009- present  ESTRO
    • 2009- present  ASTRO
    • 2011- present  COSA: Clinical Oncology Society Australia
    • 2011- present  COG: Children’s Oncology Group
    • 2011- present  AMA: Australian Medical Association
    • 2012-present   ALLG: Australasian Leukaemia and Lymphoma Group
    • 2012- present  ILROG: International Lymphoma Radiation Oncology Group (Foundation Member)
    • 2015-present   ANZGOG: Australia New Zealand Gynaecological Oncology Group

Publications (Peer Reviewed Journals):

    • Thompson SR, Veness MJ, Morgan GJ, Shannon J, Kench JG. Leptomeningeal Carcinomatosis from Squamous Cell Carcinoma of the Supraglottic Larynx. Australasian Radiology 2003; 47:325-330.
    • Thompson S, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix by a review of clinical practice guidelines and primary evidence. Cancer 2006; 107:2932-2941.
    • Thompson SR, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Estimation of the optimal brachytherapy utilization rate in the treatment of malignancies of the uterine corpus by a review of clinical practice guidelines and primary evidence. International Journal of Radiation Oncology Biology Physics 2008; 72:849-858.
    • Thompson SR, Delaney GP, Gabriel GS, Jacob S, Barton MB. Estimation of the Optimal Brachytherapy Utilization Rate in the Treatment of Vaginal Cancer and Comparison with Patterns of Care. Journal of Medical Imaging and Radiation Oncology 2012; 56:483-489.
    • Thompson SR, Delaney GP, Gabriel GS, Jacob S, Barton MB. Estimation of the Optimal Brachytherapy Utilization Rate in the Treatment of Gynaecological Cancers and Comparison with Patterns of Care. International Journal of Radiation Oncology Biology Physics 2013; 85:400-405
    • Hwang S, Warrier S, Thompson SR, Crowe P. Core Biopsy in Retroperitoneal Sarcomas: Safety and Accuracy. Asia Pacific Journal of Clinical Oncology 2013; doi:10.1111/ajco.12125
    • Thompson SR, Delaney GP, Gabriel GS, Barton MB. Patterns of Care Study of Brachytherapy in New South Wales: Cervical Cancer Treatment Quality depends on Caseload. Journal of Contemporary Brachytherapy 2014; 6:28-32.
    • Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. UNSW South Western Sydney Clinical School Paper of the Year. Radiotherapy and Oncology. 2014; 112:140-144.
    • Thompson SR, Delaney GP, Gabriel GS, Izard MA, Hruby G, Jagavkar R, Bucci J, Barton MB. Prostate Brachytherapy in New South Wales: Patterns of Care Study and Impact of Caseload on Treatment Quality. Journal of Contemporary Brachytherapy 2014; 6:344-349.
    • Thompson SR, Delaney GP, Gabriel GS, Barton MB. Patterns of care study of brachytherapy in New South Wales: malignancies of the uterine corpus. Journal of Contemporary Brachytherapy 2015; 7:224-230
    • Lehane C, Ho F, Thompson SR, Links D, Lewis C, Smee R, Parasyn A, Friedlander M, Williams J, Crowe P. Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. Journal of Medical Imaging and Radiation Oncology 2016; 60:539-544
    • Thompson SR, Delaney GP, Jacob S, Shafiq J, Wong K, Hanna TP, Gabriel GS,  Barton MB. Estimation of the Optimal Utilization Rates of Radical Prostatectomy, External Beam Radiotherapy and Brachytherapy in the Treatment of Prostate Cancer By a Review of Clinical Practice Guidelines. Radiotherapy and Oncology. 2016; 118:118-121
    • CR Lemech, R Williams, SR Thompson, B McCaughan, M Chin. Treatment of Breast Cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Research Notes. 2016; 9:386-390.
    • Tang S, Ng C, Smee R, Thompson SR. Metastatic basal cell carcinoma: A case series and review of the literature. Australasian Journal of Dermatology. 2017; 58: e40-e43. DOI: 10.1111/ajd.12459
    • Tam M, Thompson SR, Schipp D, Bae S, Crowe PJ. Patterns of care of superficial soft tissue sarcomas: it is not always just a lump. ILP project. Asia-Pac JCO. 2018; 14:e472-478.
    • Morade B, Thompson SR, Brighton T. Role of radiotherapy in management of gingival infiltration by chronic myelomonocytic leukaemia. Internal Medicine Journal. 2018; 48: 223-224.
    • Hanna T.P, Shafiq J, Delaney G.P, Vinod, S. K, Thompson, S.R, Barton M.B. The Population Benefit of Evidence-based Radiotherapy Programs: 5-year Local Control and Overall Survival Benefits. Radiotherapy and Oncology. 2018; 126 (2): 191-197.
    • Chin V, Fulham M, Herzberg M, Jackson M, Lindeman R, Brighton T, Kidson-Gerber G, Wegner E, Cheung C, MacCallum S, Williams J, and Thompson SR. Impact of salvage treatment modalites in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. JMIRO. 2018; 62: 432-439.
    • Thompson SR, Lee ISY, Carroll S, Bishop S, Douglas P, Lam F, Brown C, Williams J, Goldstein D. Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ANZ Journal of Surgery. 2018; 88:870-875.
    • Lubotzky FP, Butow P, Hunt C, Costa D, Laidsaar-Powell R, Carroll S, Thompson SR, Jackson M, Tewari A, Nattress K, Juroskova I. A psychosexual rehabilitation booklet increases vaginal dilator adherence and knowledge in women undergoing pelvic radiation therapy for gynecological or anorectal cancer: A randomized controlled trial. Clinical Oncology. Accepted for publication. 2018.
    • J Long, D Debono, R Williams, E Salisbury, S O’Neill, E Eykman, J Butler, R Rawson, SR Thompson, J Braithwaite, M Chin, N Taylor. Using behaviour change and implementation science to address low referral rates in oncology.
    • Cancer Institute NSW – NSW Premier’s Awaards for Outstanding Cancer Research: Excellence in Translational Cancer Research Award. BMC Health Services Research. Accepted for Publication. 2018.

Publications (Government and Other Reports):

    • Thompson S, Barton M, Delaney G. Estimating the optimal utilization of brachytherapy for the treatment of cancer. Report submitted to NSW Health. CCORE. 2004.
    • Thompson S, Barton M. Optimal utilization of permanent seed brachytherapy for the treatment of prostate cancer. Report submitted to NSW Health. CCORE. 2009.
    • Barton M, Jacob S, Shafiq J, Wong K, Thompson SR, Delaney G, Hanna T. Review of Optimal Radiotherapy Utilisation Rates. Report prepared for Australian Government Department of Health and Aging. CCORE, The Ingham Institute. 2012. http://www.inghaminstitute.org.au/
    • Gynaecology Oncology Radiation Oncology Collaborative (GOROC), Faculty of Radiation Oncology, RANZCR. Position Paper on Image Guided Brachytherapy (IGBT) for Cervical Cancer. Royal Australian and New Zealand College of Radiologists. 2016. http://www.ranzcr.edu.au/resources/professional-documents/guidelines

Publications (Co-Authored Guidelines):

Publications (Other):

    • Graham P, Thompson SR. Lymphatics. In: Applied Sciences of Oncology [CD-ROM. Vienna: International Atomic Energy Agency (IAEA); CD-ROM. 2006.
    • Thompson SR. A Comparison Between Optimal and Actual Utilization of Brachytherapy in the Treatment of Cancer in New South Wales. PhD Thesis, Faculty of Medicine, University of New South Wales. 2010.

Research Presentations/Abstracts:

    • Thompson SR, Turner SL, Gebski V. Assessment of Urinary Morbidity Following Low Dose Rate Prostate Brachytherapy Using the International Prostate Symptom Score. Oral presentation, RANZCR 52nd Annual Scientific Meeting, Melbourne. 2001.
    • Thompson SR, Turner SL, Gebski V. Assessment of Urinary Morbidity Following Low Dose Rate Prostate Brachytherapy Using the International Prostate Symptom Score. Oral presentation, Urological Cancer Organization Conference, Orange, NSW. 2002.
    • Thompson SR, Veness MJ, Morgan GJ, Shannon J, Kench JG. Leptomeningeal Carcinomatosis from Squamous Cell Carcinoma of the Supraglottic Larynx. Poster presentation, RANZCR 53rd Annual Scientific Meeting, Adelaide. 2002.
    • Thompson S, Delaney G, Jacob S, Barton M. Optimal brachytherapy utilization. Oral presentation, Merck Sharp and Dohme Poster Competition, Faculty of Medicine, University of New South Wales. 2004. Awarded Certificate of Merit for Oral Presentation – CVS and Cancer.
    • Thompson S, Delaney G, Jacob S, Barton M. Optimal brachytherapy utilization. Poster presentation, RANZCR 55th Annual Scientific Meeting, Perth. 2004.
    • Thompson S, Delaney G, Jacob S, Barton M. Optimal brachytherapy utilization. Oral presentation, Australasian Brachytherapy Group 14th Annual Scientific Meeting, Alice Springs. 2005.
    • Thompson S, Delaney G, Jacob S, Barton M. Optimal brachytherapy utilization. Oral presentation, Postgraduate Student Research Seminar, Faculty of Medicine, Southwestern Sydney Clinical School, University of New South Wales. 2005.
    • Thompson S, Delaney G, Jacob S, Barton M. Optimal gynaecological brachytherapy utilization. Oral presentation, Gynaecology Interdisciplinary Radiation Oncology Workshop, Liverpool Hospital, Sydney. 2005.
    • Thompson S, Gabriel GS, Das P, Izard M, Stricker P, Barton M. Patterns of Care in Brachytherapy in NSW in 2003. Oral presentation, RANZCR 56th Annual Scientific Meeting, Sydney. 2005.
    • Thompson S, Gabriel GS, Das P, Izard M, Stricker P, Barton M. Patterns of Care in Brachytherapy in NSW in 2003. Oral presentation, Postgraduate Student Research Seminar, Faculty of Medicine, South Western Sydney Clinical School, University of New South Wales. 2006.
    • Thompson S, Gabriel GS, Das P, Izard M, Stricker P, Barton M. Patterns of Care in Brachytherapy in NSW in 2003. Oral presentation, New South Wales Radiotherapy Club, RANZCR. 2006.
    • Ng C, Smee R, Thompson S. Metastatic basal cell carcinoma: A case series from a single institution and review of the literature. Poster presentation, RANZCR 57th Annual Scientific Meeting, Singapore. 2006.
    • Thompson S, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Gynaecological Brachytherapy Utilization – Optimal, Actual…..and the Difference between the Two. Oral presentation, “Back to POW”, Prince of Wales Hospital Department of Radiation Oncology 40th Anniversary Scientific Meeting.  Sydney. 2007.
    • Thompson S, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Prostate Brachytherapy Utilization – Optimal, Actual….. and the Difference between the Two. Oral presentation, Australasian Brachytherapy Group 18th Annual Scientific Meeting, Surfers’ Paradise. 2009.
    • Thompson S, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. NSW Brachytherapy Patterns of Care Study: Impact of Caseload on Treatment Quality. Oral presentation, RANZCR 61st Annual Scientific Meeting, Perth. 2010.
    • Ho F, Links D, Thompson S, Yang JL, Lewis C, Smee R, Parasyn A, Crowe P. Neoadjuvant Chemoradiation (Modified Eilber Protocol) Compared to Adjuvant Radiotherapy in the Treatment of Extremity Soft Tissue Sarcoma. Poster presentation, Australian Sarcoma Group/Australasian Sarcoma Study Group Annual Scientific Meeting, Melbourne. 2011.
    • Hwang S, Warrier S, Thompson S, Crowe P. Core Biopsy in Retroperitoneal Sarcomas: Safety and Accuracy. Poster presentation, Annual Scientific Congress, Royal Australasian College of Surgeons, Kuala Lumpur. 2012.
    • Lee ISY, Goldstein D, Carroll S, Douglas P, Lam F, Newstead G, Brown C, Williams J, Thompson SR. Radiotherapy for anal squamous cell carcinoma: Impact of radiotherapy fields on patterns of failure. Oral presentation, RANZCR 63rd Annual Scientific Meeting, Cairns. 2012.
    • Gholamrezaei L, Stuart K, Crowe P, Smee P, Milross C, Yang JL, Choo E, Thompson SR. Initial and Ultimate Local Control of Desmoid Tumours with Multimodality and Salvage Treatments: 40 years Experience of the Prince of Wales Hospital Soft Tissue Sarcoma Service. Poster presentation, Australian Sarcoma Group/Australasian Sarcoma Study Group Annual Scientific Meeting, Sydney. 2012.
    • Harris M, Thompson SR, Ng C, Vinod SK, Jackson M, Robertson G, Farrell R and Hacker NF. Stage IIIC endometrial cancer – standard adjuvant pelvic radiotherapy or extended field? Oral presentation, ASGO 28th Annual Scientific Meeting, Darwin. 2013.
    • Hesselberg G, Goldstein D, Haghighi K, Truskett P, Wong W and Thompson S. Curative Treatment of Oligometastatic Liver and Lung Disease from Anal Squamous Cell Carcinoma: a Case Series. Poster Presentation, IHPBA 11th World Congress, Seoul, Korea. 2014.
    • Yap ML, Delaney G, Shafiq J, Jacob S, Wong KHW, Thompson S, Hanna T, Barton M. Estimating the global need for radiotherapy: A study as part of The Global Task Force in Radiotherapy for Cancer Control (GTFRCC). Oral presentation, RANZCR 65th Annual Scientific Meeting, Melbourne. 2014.
    • Hanna TP, Delaney GP, Thompson SR, Barton MB. Population Benefit of Optimally Utilized Radiotherapy for Prostate Cancer: Biochemical Control and Overall Survival. Oral presentation, Canadian Association of Radiation Oncology, Annual Scientific Meeting, Kelowna, BC, Canada. 2015.
    • Tam M, Thompson SR, Schipp D, Bae S, Crowe PJ. Patterns of care of superficial soft tissue sarcomas: It’s not always just a lump. ILP project. Poster presentation, Australian Sarcoma Group/Australasian Sarcoma Study Group Annual Scientific Meeting, Brisbane. 2015.
    • Lubotzky F, Butow P, Hunt C, Carroll S, Thompson SR, Jackson M, Tewari A, Juroskova I. A randomised controlled trial of a psycho-educational booklet to improve pschosexual adjustment for women undergoing pelvic radiotherapy for gynaecological or anorectal cancer. Winner, Best of the Best (Education Category). Oral presentation, Clinical Oncology Society of Australia, Annual Scientific Meeting, Hobart, Australia. 2015.
    • Oar AJ, Wong W, Chen C, Haghighi KS, Thompson S, Goldstein D. Stereotactic body hypofractionated radiotherapy for inoperable pancreatic cancer, with or without metastases. 12th World Congress of International HepatoPancreaticoBiliary Association, Sao Paulo, Brazil. 2016.
    • Chin V, Lindeman R, Herzberg M, Brighton T, Cheung C, MacCallum S, Kidson-Gerber G, Wegner E, Fulham M, Jackson M, Thompson SR. The impact of salvage treatment modality in patients with positive PET after RCHOP chemotherapy for DLBCL. Poster presentation, RANZCR 67th Annual Scientific Meeting, Gold Coast. 2016.
    • Lubotzky F, Butow P, Hunt C, Carroll S, Thompson SR, Jackson M, Tewari A, Juroskova I. Improving post-radiotherapy adjustment for women with gynaecological or anorectal cancer: A RCT of a psycho-educational booklet. Oral presentation, RANZCR 67th Annual Scientific Meeting, Gold Coast. 2016.
    • Lehane C, Ho F, Thompson SR, Links D, Lewis C, Smee R, Parasyn A, Friedlander M, Williams J, Crowe P. Preoperative chemoradiotherapy for soft tissue sarcoma, the Prince of Wales experience. Invited presentation. Australian Sarcoma Group/Australasian Sarcoma Study Group Annual Scientific Meeting, Sydney. 2016. Winner, Choong- Dickinson Sarcoma Poster Prize
    • Moradi B, Thompson SR, Brighton T. Role of Radiotherapy in Management of Gingival Infiltration by CMML. Poster presentation, HAA - Haematology Society of Australia and New Zealand, Australian & New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and Haemostasis, Melbourne. 2016
    • Chin V, Lindeman R, Herzberg M, Brighton T, Cheung C, MacCallum S, Kidson-Gerber G, Wegner E, Fulham M, Jackson M, and Thompson SR. The impact of salvage treatment modality in patients with positive PET after RCHOP chemotherapy for DLBCL. Poster presentation, HAA - Haematology Society of Australia and New Zealand, Australian & New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and Haemostasis, Melbourne. 2016
    • V. Chin, R. Lindeman, M. Fulham, M. Jackson, T. Brighton, G. Kidson-Gerber, M. Hertzberg, S. MacCallum, C. Cheung, E. Wegne, J. Williams and S.R. Thompson. The Impact of Salvage Treatment Modality in Patients with Positive PET After R-CHOP Chemotherapy for Aggressive B-cell Non-Hodgkin’s Lymphoma. Poster presentation. Radiotherapy in Modern Lymphoma Management, International Lymphoma Radiation Oncology Group, Peter MacCallum Cancer Centre, Melbourne. 2017
    • D Inwood, DC Stewart, SR Thompson, SJ Downes. VMAT for total scalp treatment using 3D printed bolus. Oral presentation, EPSM (Engineering and Physical Sciences in Medicine Conference), Hobart. 2017
    • Fiona S Lau, Stephen R Thompson, Neera S Jain, Geoff Wilcsek, Ian C Francis. Acquired Defective Abduction without Diplopia in a 42-year-old lady: Cumberbatch’s Rule Rules. Oral presentation. NOSA (Neuro-Ophthmalmology Society of Australia), Melbourne. 2018
    • Shuttleworth C, Thompson SR, Kidson-Gerber G. Relapsed Myeloid Sarcoma: Prolonged clinical remission with FDG-PET directed palliative radiotherapy. Poster presentation.  Blood, Brisbane. 2018
    • Wake J, Bhadri V, Thompson SR, Pryor D, Bae S, Maher A, Hong, A. CIC-DUX rearranged round cell tumours: a review of the Australian experience. Poster presentation. Australasian Sarcoma Study Group Annual Scientific Meeting, Perth. 2018.
Suite 713, POWP Hospital, Barker St
Randwick NSW 2031